Characterization of the Pharmacokinetics and Physiological Effects of Tapentadol in Horses Authors: Annabella D Lynch, Khursheed R Mama, Dan S McKemie, Phillip H Kass, Heather K Knych Published: 2026 ABSTRACT ABSTRACTTapentadol is a dual mechanism analgesic utilizing both μ‐opioid receptor (MOR) agonism and norepinephrine reuptake inhibition (NRI). This study evaluated the pharmacokinetics and pharmacodynamics of tapentadol as a potential analgesic with the goal of treating pain in horses. Pharmacokinetics of both tapentadol and tapentadol‐O‐glucuronide were elucidated. Six horses received three separate escalating single oral doses (1, 3, and 5 mg/kg) and a single intravenous (0.32 mg/kg) dose of tapentadol in a four‐period sequential design. Concentrations of tapentadol and tapentadol‐O‐glucuronide were determined using liquid chromatography–tandem mass spectrometry. The maximum concentrations (mean ± SD) in plasma following administration of 1, 3, 5 mg/kg oral tapentadol were 7.98 ± 6.95, 39.8 ± 53.8, and 210.6 ± 234.4 ng/mL at 0.75, 0.63, and 0.38 h, respectively. Maximum plasma concentration (mean ± SD) after a single 0.32 mg/kg IV dose was 339.2 ± 83.5 ng/mL. The maximum concentrations of tapentadol‐O‐glucuronide following single 1, 3, and 5 mg/kg oral doses and a single 0.32 mg/kg IV dose of tapentadol were 532.6 ± 171.4, 1169.4 ± 345.4, 1559.5 ± 574.6, and 226.4 ± 51.5 ng/mL at times 6.0, 6.0, 7.0, and 0.5 h. Tapentadol was well‐tolerated at all doses.Keywords: analgesia, horse, pharmacodynamics, pharmacokinetics, Tapentadol Introduction In horses, opioid administration can result in respiratory, gastrointestinal and central nervous system depression (Gooding and Whistler 2024). In addition, repeated opioid administration may result in the development of tolerance and hyperalgesia, reducing treatment efficacy over time and necessitating an increase in dose (Rowbotham and Wallace 2020). Opioids demonstrate variable efficacy for the treatment of pain with neuropathic and/or inflammatory origins (Cooper et al. 2017; McNicol et al. 2013). In humans, neuropathic pain may arise as a sequalae of cancer treatment, postviral infection, and diabetes (Callaghan et al. 2012; Li et al. 2023; Ragozzino et al. 1982). Neuropathic pain is also present in equine diseases including laminitis and trigeminal nerve pain (idiopathic headshaking) (Aleman et al. 2013; Baxter 1994). Equine laminitis has both neuropathic and inflammatory components, making pure opioids a less‐than‐optimal treatment option (Jones et al. 2007). The mixed action opiate/serotonin‐norepinephrine reuptake inhibitor (SNRI) tramadol, and anticonvulsants such as gabapentin have garnered some interest in the treatment of equine neuropathic pain. However, reports of gabapentin's analgesic efficacy in horses has been mixed, and some equine studies suggest poor bioavailability and nonlinear absorption, both of which could make gabapentin therapy in this species challenging (Di Cesare et al. 2023; Gold et al. 2020; Terry et al. 2010; Young et al. 2020). Similarly, tramadol has poor oral bioavailability and nonlinear kinetics (Guedes et al. 2014). This coupled with inconclusive reports of efficacy make tramadol sub‐optimal for the treatment of pain, in horses (Guedes et al. 2016). Tapentadol is a centrally‐acting analgesic with a dual mechanism of action. In humans, in addition to activation of the MOR receptor (Ki = 0.1 mM), tapentadol also inhibits norepinephrine reuptake (Ki≈0.48 μM for norepinephrine transporter in vitro) (Sadeghi et al. 2015; Tzschentke et al. 2007). In vitro, tapentadol has a lower affinity for the MOR compared to morphine (50‐fold less in humans) but its analgesic potency in vivo is only 2‐3× less than morphine (Giorgi 2012). This finding has led to speculation that the inhibition of norepinephrine re‐uptake contributes greatly to the analgesic properties of tapentadol (Tzschentke et al. 2009). The lower affinity for the MOR could be beneficial in that adverse effects associated with activation of this receptor (e.g., dose‐related excitement and decreases in gastrointestinal motility) may be less than that observed with pure MOR agonists, such as morphine (Giorgi 2012). This may be especially useful in horses, a species particularly susceptible to dose‐related opioid induced adverse gastrointestinal effects. Although in humans tapentadol has reduced efficacy compared to morphine, efficacy of tapentadol immediate release (IR) was found to be noninferior compared to that of oxycodone HCl immediate release formulation for the treatment of osteoarthritis and in the treatment of acute postoperative pain following shoulder surgery (Hartrick et al. 2009). Recently, the analgesic efficacy of tapentadol in horses with grade 3–5 osteoarthritis was reported (Costa et al. 2024). In that study, investigators reported significant decreases in graded lameness compared to baseline in horses administered 0.5 mg/kg of oral tapentadol for 4 weeks. Additionally, tapentadol appeared to be well‐tolerated. The study reported by Costa et al. (2024) is encouraging; however, further studies describing the pharmacokinetics and pharmacodynamics of tapentadol in horses are warranted before this drug can be recommended for clinical use. To that end, the objectives of the current study were (1) to characterize the pharmacokinetics of tapentadol and metabolites, and (2) to assess select physiological effects, with the goal of adding to the limited information describing administration of tapentadol to horses. Materials and Methods Animals Six healthy university‐owned horses (3 geldings and 3 mares; age 5–17 years; weight 522.2–713.8 ± 69.2 kg) were studied. Physical examination, complete blood count, and clinical chemistry were performed prior to the commencement of the study to assess general health status. All blood analyzes were conducted by the Clinical Pathology Laboratory of the William R. Pritchard Veterinary Medical Teaching Hospital of the University of California, Davis, using standard protocols. Horses were not administered any therapeutic drugs for a minimum of 2 weeks prior to commencement of the study. All horses were kept in 12 × 12 ft stalls immediately prior to drug administration and until the 24 h time point. Horses had free access to approximately 10–15 pounds of grass hay 30 min prior to drug administration and had free access throughout and following the dosing period. Water continued to be available ad libitum for the entirety of the study. The study was conducted in accordance with the Institutional Animal Care and Use Committee of the University of California at Davis (#23392). Study Design, Drug Administration and Sample Collection Since the safety of tapentadol in horses had not been reported when this study was conducted, a four‐period sequential design was utilized with doses administered in an escalating fashion. Oral doses were administered in the following order: 1, 3, and 5 mg/kg. In the last phase, horses received a single intravenous (IV) dose of 0.32 mg/kg of tapentadol (0.35 mg/kg of tapentadol HCl). A minimum 2‐week washout period was observed between doses. Doses were chosen based on reports describing substantially higher tapentadol administration in other species (Howard et al. 2018; Lee et al. 2013) and taking into consideration the sensitivity of horses to other opioids. Oral tablets (100 mg/tab Nucynta, Collegium Pharmaceutical) were administered in grain (Purina Omolene #200 Performance Horse Feed) or with horse treats (Purina Apple and Oat‐Flavored). The actual dose for each horse was rounded up or down, as appropriate to prevent cutting tablets. Doses ranged from 0.99 to 1.15 mg/kg, 2.99–3.20 mg/kg, and 4.95–5.06 mg/kg for the 1, 3, and 5 mg/kg dose groups, respectively. Horses were observed throughout the dosing period to ensure all tablets were consumed. IV administration was included to allow for determination of bioavailability. The IV dose was 0.35 mg/kg tapentadol HCl (0.32 mg/kg of the active ingredient), determined based on the availability of the pharmaceutical grade tapentadol powder. Since an injectable formulation is not commercially available, tapentadol was compounded for intravenous administration. Pure pharmaceutical grade tapentadol HCl powder (Lipomed Inc., Cambridge, MA) was diluted in sterile 0.9% saline. The solution was subsequently filter sterilized (Acrodisc 25 mm w/0 2 μm Supor STRL) before dosing. The dosing solution was administered within 1 h of formulation. Following dosing, the concentration of the formulation was confirmed within 3 h of compounding by liquid chromatography tandem mass spectrometry (LC–MS/MS) as described below. A single catheter was placed for sample collection prior to oral administration and was removed following the 18 h blood collection. The remaining samples were collected via direct venipuncture from the jugular vein. For IV administration, two catheters were placed with one used for drug administration and the second for sample collection. The dosing catheter was removed following dosing, and the second catheter was removed following the 18 h blood collection, with the remaining samples collected via direct venipuncture from the jugular vein. Blood samples were collected in EDTA blood tubes (Kendall/Tyco Healthcare, Mansfield, MA) at time 0 (prior to drug administration) and at 5, 10, 15, 30, and 45 min and 1, 2, 3, 4, 6, 8, 12, 18, 24, 30 and 72 h postadministration in all groups. Samples were placed on ice and were centrifuged within 1 h. Samples were centrifuged (4300 rpm/3102 g) for 10 min at 4°C and plasma collected and frozen at −20°C until analysis. All samples were analyzed within 1 month of collection. Determination of Drug and Metabolite Concentrations Chemicals and Reagents The analytical reference standard for tapentadol and tapentadol‐O‐glucuronide was manufactured by Cerilliant (Round Rock, TX) and purchased from Sigma‐Aldrich (St. Louis, MO) as 1 and 0.1 mg/mL solutions respectively. Internal standard D3‐tapentadol was manufactured by Cerilliant and purchased from Sigma‐Aldrich as a 0.1 mg/mL solution. All solvents were HPLC grade. Acetonitrile (ACN) and water were purchased from Burdick and Jackson (Muskegon, MI). Methanol and buffer reagents were purchased from Fisher Scientific (Fair Lawn, NJ). Formic acid, 98%, was purchased from Sigma‐Aldrich. Plasma Sample Analysis Tapentadol and tapentadol‐O‐glucuronide were combined into a single final working solution. Calibration curves and negative control samples were prepared for each assay. Plasma calibrators were made by dilution of working standard solutions with drug‐free equine plasma to concentrations between 0.1 and 3000 ng/mL. Quality control samples were made by fortifying drug‐free equine plasma with analyte at four concentrations within the calibration curve. Samples were prepared and precipitated by diluting 500 μL of sample plasma with 500 μL of ACN and 1 M acetic acid (9:1, v:v), with diluent containing 0.05 ng/μL of D3‐tapentadol internal standard. Following dilution, samples were vortexed for 1.5 min and then refrigerated at 4°C for 20 min. Following refrigeration, samples were vortexed for another minute, centrifuged (4300 rpm/3102 g) for 10 min at 4°C, and 15 μL of organic layer was injected into the liquid chromatography–tandem mass spectrometry (LC–MS/MS) system. The analyte concentrations were measured in plasma by LC–MS/MS using positive heated electrospray ionization (H‐ESI[+]). Quantitative analysis was performed on a TSQ Altis triple quadrupole mass spectrometer coupled with a Vanquish liquid chromatography system (Thermo Scientific, San Jose, CA). Product masses and collision energies of each analyte were optimized by infusing the standards into the TSQ Altis. Chromatography employed an ACE3 C18 10 cm × 2.1 μm column (Mac‐Mod Analytical, Chadds Ford, PA) and a linear gradient of ACN in water with a constant 0.2% formic acid at a flow rate of 0.35 mL/min. Acetonitrile concentration was held at 1% for 0.2 min at a flow rate of 0.350 mL/min, ramped to 90% over 5.8 min and held at 90% with a 0.350 mL/min flow rate for 0.2 min. Conditions were then re‐equilibrated to 1% ACN for 3 min at a flow rate of 0.400 mL/min. The retention times for tapentadol and tapentadol‐O‐glucuronide were 3.3 and 2.9 min, respectively. Detection and quantitation were conducted using selective reaction monitoring (SRM) of initial precursor ion for tapentadol (m/z 222.2), tapentadol‐O‐glucuronide (m/z 398.3) and D3‐tapentadol (m/z 225.2). The response for the product ions of tapentadol (m/z 107.0), tapentadol‐O‐glucuronide (m/z 107.1) and D3‐tapentadol (m/z 107.071, 120.9) were plotted. Peak integration was conducted using Quan Browser software (Thermo Scientific). Pharmacokinetic Analysis Noncompartmental analysis (NCA) was performed for both drug and metabolite using Phoenix WinNonlin, v8.3 (Certara, Princeton, NJ). Actual administered doses for individual horses (described above) were used for pharmacokinetic analyzes. For the IV administration, the dose of the active ingredient (tapentadol; 0.32 mg/kg) was used since the oral dose was based on the active ingredient. The Cmax and AUClast are reported as absolute values and normalized for dose (Cmax/D and AUClast/D) for comparison between dose groups. Only plasma concentrations above the limit of quantitation (LOQ) were used for determination of pharmacokinetic parameters. The terminal half‐life was calculated using the formula: where λ z is the terminal rate constant defined by the terminal slope of the plasma concentration–time curve. The area under the curve from time 0 to the last time point (AUClast) was determined using the log up‐linear down trapezoidal method. The oral bioavailability (F) for each horse at each dose was calculated using the formula: where AUCoral represents AUClast following oral administration and AUCIV is AUClast following intravenous administration. Actual administered doses for each horse were used in the calculation of bioavailability. Total systemic clearance was calculated using the formula: For the oral doses, derived clearance was calculated for individual horses at each dose for comparison of linearity with respect to clearance between doses. The metabolic ratio (MR) was calculated using the formula: The AUC is AUClast. Behavioral Observations and Instrumentation for Physiological Assessments Subjective assessments of disposition (sedation, ataxia, ear and eye position, discomfort) were made by observers familiar with normal behaviors in these horses continuously until 2 h postadministration, and then at each blood sample collection timepoint thereafter. Assessments were made prior to entering the stall for blood sample collections by observers who were unblinded with respect to treatment. Fecal output was noted. Thirty minutes prior to dosing, Holter monitors (Forrest Medical, East Syracuse, NY) were placed on all horses for continuous recording of heart rate. Horses were acclimatized to Holter monitors for a minimum of 20 min prior to collection of baseline data (30 min prior to drug administration). Heart rate was continuously monitored from baseline (represented in Figure 3 as the −0.08 h timepoint) until 480 min (8 h) postdrug administration. Heart rate (mean ± SD) over time following administration of tapentadol oral doses of (A) 1 mg/kg; n = 5, (B) 3 mg/kg; n = 5, and (C) 5 mg/kg; n = 6, and (D) intravenous dose of 0.32 mg/kg; n = 6. * indicates a statistically significant (p < 0.05) change from baseline. Step counters (StepWatch4; Modus Health, Edmonds, WA), positioned on the lateral side of the lower left front and lower right hind legs, were placed on all subjects approximately 30 min prior to dosing, and horses were allowed to acclimatize to the devices for 20 min prior to baseline data collection (30 min prior to drug administration). Step counters were used to continuously record locomotion. All counters were removed at 8 h postdrug administration. Step counts were averaged from baseline, 10 min before drug administration (represented in Figure 2 as the 0 min timepoint) until 480 min (8 h) postdrug administration. Number of steps per 10 min (mean ± SD) following administration of tapentadol oral doses of (A) 1 mg/kg; n = 4 horses, (B) 3 mg/kg; n = 4 horses, and (C) 5 mg/kg; n = 2 horses and (D) intravenous dose of 0.32 mg/kg; n = horses. * indicates a statistically significant (p < 0.05) change from baseline. Gastrointestinal borborygmi were scored and recorded in all four quadrants prior to and at 30 and 45 min, and 1, 2, 4, 6, 8, and 24 h postdrug administration. Borborygmi were assessed via auscultation performed for 15 s at each abdominal quadrant. Each quadrant was assigned a GI borborygmi score ranging from 0 to 4, with 0 being absent and 4 being increased sounds (Hamamoto‐Hardman et al. 2020). Statistical Analysis Statistical analysis was conducted using commercially available software (Stata/BE 17.0, StataCorp, TX, United States). Differences in pharmacokinetic parameters between oral doses were assessed. For pharmacodynamic assessments, all times postadministration were compared to baseline within a dose group. All analyzes were done with a mixed effects analysis of variance in which horse was the random effect and fixed effects were either time conditional on treatment or treatment. For pharmacodynamic assessments, post hoc comparisons were conducted using a Bonferroni multiple comparison adjustment to preserve a nominal significance level of p < 0.05. Heart rate was variable and therefore was transformed to inverse heart rate (i.e., 1/heartrate) to improve normalization of the model‐generated residuals. Similarly, due to high variability in step counts the data was transformed via a square root transformation (i.e., 10‐min average step count) to improve normalization of model‐generated residuals. Results Instrument responses for both analytes were linear and gave correlation coefficients of 0.99 or better. Quality control samples were assayed in replicates (n = 6) for determination of precision and accuracy of the assay. Accuracy was reported as percent nominal concentration and precision as percent relative standard deviation. Accuracy and precision for both matrices were considered acceptable based on the Food and Drug Administration's guidelines for Bioanalytical Method Development (Table 1) (Fda and Cder 2018). The LOQ was the lowest calibrator that could be measured with acceptable precision (concentration ≤ 20% of the coefficient of variation (CV); accuracy within 20% of the nominal concentration). The limit of detection (LOD) was established based on the lowest calibrator with a 3:1 signal to noise ratio. The LOQ was 0.01 ng/mL for tapentadol and 0.1 ng/mL for tapentadol‐O‐glucuronide. The LOD of tapentadol was 0.03 ng/mL. The LOD of tapentadol‐O‐glucuronide was 0.05 ng/mL. All other preadministration samples across doses did not contain detectable levels of tapentadol. TABLE 1Accuracy and precision values for LC–MS/MS analysis of tapentadol, and tapentadol‐O‐glucuronide in equine plasma.AnalyteMatrixConcentration (ng/mL)Accuracy (% nominal concentration)Precision (% relative SD)TapentadolPlasma0.3097.04.010.01014.050.099.03.0Tapentadol‐O‐glucuronidePlasma0.301029.010.01092.050.01012.0 Accuracy and precision values for LC–MS/MS analysis of tapentadol, and tapentadol‐O‐glucuronide in equine plasma. Plasma concentrations of tapentadol following oral and IV administration are depicted in Figure 1A. Following oral administration plasma tapentadol concentrations for all animals fell below the LOD by 72 h postadministration. Plasma tapentadol‐O‐glucuronide concentrations however remained above the LOQ in all horses for the 1 and 5 mg/kg doses at the 72 h (last) timepoint but were below the LOQ in two horses dosed at 3 mg/kg. Plasma concentrations (mean ± SD) over time of tapentadol (A) and tapentadol‐O‐glucuronide (B) following a single intravenous administration of 0.32 mg/kg and oral administrations of 1, 3, and 5 mg/kg to six horses. The inset graph represents concentration over time from 0 to 5 h. Dash line represents concentrations resulting in analgesia in humans. Pharmacokinetic parameters for tapentadol are listed in Table 2. The maximum plasma concentrations (Cmax) were significantly lower following oral administration of 1 mg/kg (p = 0.011) and 3 mg/kg (p = 0.042) of tapentadol compared to 5 mg/kg. There was a large degree of variability in Cmax between horses within a dose with %CV values of 87.0, 135.3, and 111.3 for doses of 1, 3, and 5 mg/kg, respectively. The AUClast was significantly lower in the 1 mg/kg (p = 0.002) and 3 mg/kg (p = 0.022) oral dose groups compared to the 5 mg/kg group. The %CV values for AUClast were 73.9, 134.6, and 88.3 for 1, 3, and 5 mg/kg, respectively. The Cmax/D was significantly higher in the 5 mg/kg group compared to the 1 mg/kg group (p = 0.042). There was not a statistically significant difference in bioavailability or the half‐life 𝛌z between dose groups. The Tmax was significantly different between the 1 mg/kg (0.75 h; median) and 5 mg/kg (0.38 h; median) dose groups (p = 0.011). The terminal half‐life was similar between dose groups. Additionally, clearance following IV administration and the derived half‐lives following oral administration of the different doses were in agreement. TABLE 2Pharmacokinetic parameters for tapentadol (mean ± SD and [%CV]); median and range for Tmax following a single oral administration of 1, 3 and 5, mg/kg and IV administration of 0.32 mg/kg tapentadol to 6 horses. Pharmacokinetic parameters calculated using actual doses administered, based on rounding to nearest 100 mg tablet.Parameter1 mg/kg PO3 mg/kg PO5 mg/kg PO0.32 mg/kg IVCmax (ng/mL)7.98 ± 6.95 (87) c 39.8 ± 53.8 (135.3) c 210.6 ± 234.4 (111.3) a , b —Cmax/D (kg × ng/mL/mg)7.64 ± 7.17 (93.9) c 13.2 ± 18.0 (137.2) c 41.8 ± 46.3 (110.9) a , b —C(0) (ng/mL)———339.2 ± 83.5 (24.6)Tmax (h)0.75 (0.50–1.0) c 0.63 (0.16–1.0)0.38 (0.25–0.75) a —AUClast (h × ng/mL)18.3 ± 13.5 (73.9) c 62.2 ± 83.7 (134.6) c 231.1 ± 204.0 (88.3) a , b 108.0 ± 25.7 (23.8)AUClast/D (h × kg × ng/mL/mg)17.4 ± 13.9 (80.2)20.5 ± 28.1 (137.1)45.9 ± 40.3 (87.8)—AUCinf (h × ng/mL)19.3 ± 14.0 (72.4) c 63.0 ± 83.8 (133.0) c 232.1 ± 204.2 (88.0) a , b 108.3 ± 25.8 (23.8)AUCextrap (%)6.45 ± 2.93 (45.4)bc 2.51 ± 1.75 (69.7) a 0.727 ± 0.641 (88.1) a 0.332 ± 0.124 (37.4)Cl (mL/min/kg)———51.6 ± 12.8 (24.9)Vdss (L/kg)———3.29 ± 0.454 (13.8)λZ (1/h)0.127 ± 0.533 (42.2)0.245 ± 0.083 (33.7)0.203 ± 0.085 (41.7)0.434 ± 0.176 (40.5)Half‐life λZ (h)6.64 ± 3.55 (53.4)3.09 ± 0.98 (31.6)4.25 ± 2.46 (57.9)1.91 ± 0.95 (49.6)F(%)5.41 ± 4.77 (88.1)6.47 ± 9.57 (147.9)12.8 ± 9.62 (75.4)—Clderived (mL/min/kg)* 51.7 ± 13.3 (25.7)51.5 ± 13.2 (25.6)51.5 ± 12.4 (24.0)—Abbreviations: AUCextrap, portion of the AUC extrapolated from the last measured timepoint to infinity; AUCinf, area under the curve extrapolated to infinity; AUClast, area under the concentration curve to the last measured time point; AUClast/D, AUClast normalized to dose; C(0), initial concentration following IV administration; Cl, total systemic clearance; Clderived, clearance collected for bioavailability; Cmax, maximal observed concentration; Cmax_D, maximal observed concentration normalized to dose; F, bioavailability; Half‐life λZ, terminal half‐life; Tmax, time of maximum observed concentration; Vdss, volume of distribution at steady state; λZ, terminal slope.*Clderived = Cl/F × F. a Indicates a statistically significant difference compared to the 1 mg/kg group. b Indicates a statistically significant (p < 0.05) difference compared to the 3 mg/kg group. c Indicates a statistically significant difference compared to the 5 mg/kg group. Pharmacokinetic parameters for tapentadol (mean ± SD and [%CV]); median and range for Tmax following a single oral administration of 1, 3 and 5, mg/kg and IV administration of 0.32 mg/kg tapentadol to 6 horses. Pharmacokinetic parameters calculated using actual doses administered, based on rounding to nearest 100 mg tablet. Abbreviations: AUCextrap, portion of the AUC extrapolated from the last measured timepoint to infinity; AUCinf, area under the curve extrapolated to infinity; AUClast, area under the concentration curve to the last measured time point; AUClast/D, AUClast normalized to dose; C(0), initial concentration following IV administration; Cl, total systemic clearance; Clderived, clearance collected for bioavailability; Cmax, maximal observed concentration; Cmax_D, maximal observed concentration normalized to dose; F, bioavailability; Half‐life λZ, terminal half‐life; Tmax, time of maximum observed concentration; Vdss, volume of distribution at steady state; λZ, terminal slope. Clderived = Cl/F × F. Indicates a statistically significant difference compared to the 1 mg/kg group. Indicates a statistically significant (p < 0.05) difference compared to the 3 mg/kg group. Indicates a statistically significant difference compared to the 5 mg/kg group. Plasma concentrations of tapentadol‐O‐glucuronide are depicted in Figure 1B and pharmacokinetic parameters are listed in Table 3 The Cmax (mean ± SD) for tapentadol‐O‐glucuronide following a single oral administration of 1, 3, and 5 mg/kg were 532.6 ± 171.5, 1169.4 ± 345.5 and 1559.5 ± 574.6 ng/mL at Tmax (median) 0.75, 0.63, and 0.38 h. TABLE 3Pharmacokinetic parameters for tapentadol‐glucuronide (mean ± SD and [CV]); median and range for Tmax following a single oral administration of 1, 3 and 5 mg/kg and IV administration of 0.32 mg/kg tapentadol to 6 horses. Pharmacokinetic parameters calculated using actual doses administered, based on rounding to nearest 100 mg tablet.Parameter1 mg/kg PO3 mg/kg PO5 mg/kg PO0.32 mg/kg IVCmax (ng/mL)532.6 ± 171.4 (32.2)1169.4 ± 345.4 (29.5)1559.5 ± 574.6 (36.8)226.4 ± 51.5 (22.7)Cmax/D (kg × ng/mL/mg)493.5 ± 156.0 (31.6)377.9 ± 106.9 (28.3)311.9 ± 117.6 (37.7)711.6 ± 162.0 (22.8)Tmax (h)6.0 (3.0–12.0)6.0 (3.0–8.0)7.0 (2.0–12.0)0.5 (0.25–0.75)AUClast (h × ng/mL)4563.4 ± 1116.4 (24.5)9248.9 ± 1335.2 (14.4)14,309.3 ± 1320.9 (9.23)723.0 ± 148.4 (20.5)AUClast/D (h × kg × ng/mL/mg)4251.7 ± 1095.2 (25.8)2997.9 ± 415.8 (13.9)2855.3 ± 275.3 (9.64)2272.8 ± 473.7 (20.8)AUCinf (h × ng/mL)4568.8 ± 1117.2 (24.5)9259.0 ± 1333.1 (14.4)14323.1 ± 1317.1 (9.20)726.1 ± 149.8 (20.6)AUCextrap (%)0.120 ± 0.086 (71.7)0.114 ± 0.123 (107.9)0.099 ± 0.050 (50.0)0.411 ± 0.140 (34.0)λZ (1/h)0.068 ± 0.025 (37.0)0.066 ± 0.016 (24.2)0.084 ± 0.028 (33.7)0.058 ± 0.023 (40.8)Half‐life λZ (h)11.3 ± 4.14 (36.5)10.9 ± 2.10 (19.3)9.17 ± 3.23 (35.2)13.3 ± 3.82 (28.7)Metabolic ratio a 345.7 ± 236.9 (68.5)351.1 ± 280.1 (79.8)146.9 ± 141.0 (96.0)6.87 ± 1.29 (18.7)Abbreviations: AUCextrap, portion of the AUC extrapolated from the last measured timepoint to infinity; AUCinf, area under the curve extrapolated to infinity; AUClast, area under the concentration curve to the last measured time point; AUClast/D, AUClast normalized to dose; Cmax, maximal observed concentration; Cmax_D, maximal observed concentration normalized to dose; Half‐life λZ, terminal half‐life; Tmax, time of maximum observed concentration; λZ, terminal slope. a Metabolic ratio = AUCtapentadol‐glucuronide/AUCtapentadol. Pharmacokinetic parameters for tapentadol‐glucuronide (mean ± SD and [CV]); median and range for Tmax following a single oral administration of 1, 3 and 5 mg/kg and IV administration of 0.32 mg/kg tapentadol to 6 horses. Pharmacokinetic parameters calculated using actual doses administered, based on rounding to nearest 100 mg tablet. Abbreviations: AUCextrap, portion of the AUC extrapolated from the last measured timepoint to infinity; AUCinf, area under the curve extrapolated to infinity; AUClast, area under the concentration curve to the last measured time point; AUClast/D, AUClast normalized to dose; Cmax, maximal observed concentration; Cmax_D, maximal observed concentration normalized to dose; Half‐life λZ, terminal half‐life; Tmax, time of maximum observed concentration; λZ, terminal slope. Metabolic ratio = AUCtapentadol‐glucuronide/AUCtapentadol. Minimal sedation (lowered head, drooping lip) was observed in two horses following oral administration of 3 mg/kg. Minimal sedation was noted in a single horse at the 5 mg/kg oral dose. Following the 1 mg/kg oral dose, step counts were significantly (p < 0.05) increased relative to baseline at 20, 30, 50, 60, 70, 80, 240, 250, 260, 330, 380, and 400 min. Following the 3 mg/kg oral dose, step counts were significantly (p < 0.05) increased relative to baseline (0 min) at 20, 50, 60, 120, 170, 180, and 210 min and significantly decreased relative to baseline from 300 to 480 min (5 to 8 h). At 5 mg/kg, step counts were significantly (p < 0.05) increased relative to baseline at 100, 130, 140, 150, 170, 210, 340, 360, 380, and 470 min. Following the IV administration, step counts were significantly (p < 0.05) increased relative to baseline at 70, 80, 100, 110, 120, 220, 230, 290, and 310 min (Figure 2). Recording difficulties with step counters resulted in incomplete data across all doses (1 mg/kg n = 5, 3 mg/kg n = 5 and 5 mg/kg n = 2 oral and 0.32 mg/kg n = 5 IV). Failure of Holter monitor leads (i.e., Holter leads coming unattached) at 1 and 3 mg/kg oral doses resulted in incomplete (n = 5 for both) datasets. This resulted in less than 6 horses at some time points. Heart rate was significantly increased, relative to baseline at 0.33 h (p = 0.008) and significantly decreased at 8 h (p = 0.014) following oral administration of 1 mg/kg (Figure 3). Significant increases in heart rate, relative to baseline, were observed in the 3 mg/kg dose group at 0.08 (p = 0.028), 0.17 (p = 0.004), and 0.25 (p = 0.026) hours (Figure 3). Oral administration of 5 mg/kg resulted in a significant increase in heart rate, relative to baseline at 0.20 h (p = 0.005) (Figure 3). Following IV administration of 0.32 mg/kg, heart rate was significantly decreased relative to baseline at 7 h (p = 0.007) postadministration (Figure 3). Gastrointestinal borborygmi were significantly decreased relative to baseline at 2 h following oral administration of 1 mg/kg (p = 006), 24 h following administration of 3 mg/kg (p = 0.001), and 4 and 6 h following administration of 5 mg/kg (p = 0.008) (Table 4). Following IV administration borborygmi were significantly (p = 0.027) increased relative to baseline at 24 h (p = 0.027; Table 4). TABLE 4Average (mean ± SD); gastrointestinal borborygmi scores (arbitrary units) at baseline and following a single oral administration of 1, 3, and 5 mg/kg and IV administration of 0.32 mg/kg tapentadol HCl to 6 horses.Time (h)1 mg/kg PO3 mg/kg PO5 mg/kg PO0.32 mg/kg IVBaseline4.6 ± 0.83.8 ± 1.13.3 ± 0.72.3 ± 1.20.54.6 ± 0.84.6 ± 0.53.6 ± 1.42.6 ± 0.50.755.0 ± 0.04.1 ± 0.94.0 ± 0.82.8 ± 1.115.0 ± 0.04.5 ± 0.54.0 ± 1.02.0 ± 0.623.0 ± 1.5* 4.3 ± 0.53.1 ± 1.12.1 ± 0.943.6 ± 1.23.6 ± 1.42 ± 0.6* 2.1 ± 0.764.0 ± 1.53.1 ± 1.12 ± 0.6* 2.5 ± 0.583.5 ± 1.53.1 ± 0.72.8 ± 0.72.0 ± 1.1244.3 ± 1.12.3 ± 0.9* 3.7 ± 1.33.3 ± 1.4* *(p < 0.05) indicates a statistically significant change from baseline. Average (mean ± SD); gastrointestinal borborygmi scores (arbitrary units) at baseline and following a single oral administration of 1, 3, and 5 mg/kg and IV administration of 0.32 mg/kg tapentadol HCl to 6 horses. (p < 0.05) indicates a statistically significant change from baseline. Discussion The current study is the first to describe the pharmacokinetics of tapentadol following administration to horses. The oral doses chosen for study (1, 3 and 5 mg/kg) were on the low end of doses studied in other species (Giorgi et al. 2012; Howard et al. 2018; Lakritz et al. 2024). These low doses were selected given the known adverse effects (i.e., dose dependent increased locomotion and decreased gastrointestinal motility) associated with opioid administration in horses. An IV administration was included for the purposes of determining bioavailability and clearance. In other species, the oral bioavailability of tapentadol is low, with reports of 4% and 32% in dogs (Giorgi et al. 2012) and humans (Göhler et al. 2013), respectively. This also appears to be the case in horses, with bioavailability ranging from 5.41% ± 4.77% (1 mg/kg) to 12.8% ± 9.62% (5 mg/kg) in the current study. The low bioavailability in dogs and humans, has been attributed to a substantial first pass effect (Howard et al. 2018; Ortho‐McNeil‐Janssen Pharmaceuticals Inc., n.d.). In dogs, investigators report rapid production of tapentadol glucuronide following oral administration, noting detection of the metabolite prior to detection of the parent compound in the blood (Howard et al. 2018). In the current study, tapentadol glucuronide was also detected early following administration of tapentadol (within 5 min), supporting high susceptibility to the first pass effect. The metabolic ratio following oral administration was much higher compared to IV administration (21–50‐fold higher), further supporting that tapentadol undergoes extensive presystemic metabolism when given orally to horses. In the presently reported study, Cmax was disproportionately higher in the 5 mg/kg dose group compared to the other groups, suggesting nonlinearity with respect to absorption. As tapentadol is susceptible to the first‐pass effect, the greater than proportionate increase in plasma concentrations may be a result of hepatic enzyme saturation at higher doses. The metabolic ratio was also much higher following administration of 1 and 3 mg/kg (~350) compared to 5 mg/kg (~147), further supporting the theory of nonlinear absorption due to saturation of presystemic metabolism. While AUClast/D and bioavailability also increased as doses increased, these changes were not statistically significant, seeming to contradict the concept of nonlinear absorption. However, it is important to note that the sample size in the current study was small and that the AUClast (%CV: 73.9, 134.6, and 8.3 for 1, 3, and 5 mg/kg, respectively) and oral bioavailability (%CV: 88.1, 147.9, and 75.4 for 1, 3, and 5 mg/kg, respectively) were both highly variable between animals. The large degree of variability may be due to differences in metabolism, as evidenced by the wide range in metabolic ratios, leading to a variable first‐pass effect between animals. In dogs and humans, absorption appears to be linear (Göhler et al. 2013; Howard et al. 2018). Study of the pharmacokinetics in a larger population of horses is warranted to assess linearity with respect to absorption. Systemic clearance determined following IV administration as well as the derived clearance (Cl corrected for bioavailability) for each oral dose were calculated in the current study. This allowed for assessment of linearity with respect to clearance across doses. Systemic clearance determined following IV administration agreed with the derived clearance values calculated for all oral doses. Furthermore, derived clearance values for all oral doses agreed, suggesting linear elimination across the doses studied. The terminal half‐life of tapentadol in horses in the current study ranged from 1.91 to 6.64 h (mean values). In dogs, the half‐life was 3.5–3.7 h (Howard et al. 2018) and in humans it was 4 h (Ortho‐McNeil‐Janssen Pharmaceuticals Inc., n.d.). The metabolic profile of tapentadol has been well described, and it undergoes extensive metabolism in dogs (Giorgi et al. 2012; Howard et al. 2018), cats (Lakritz et al. 2024), and humans (Ortho‐McNeil‐Janssen Pharmaceuticals Inc., n.d.). In dogs and humans, the major metabolite is tapentadol glucuronide with approximately 55% and 97% of the dose excreted as the glucuronide metabolite in humans (Ortho‐McNeil‐Janssen Pharmaceuticals Inc., n.d.) and dogs (Howard et al. 2018), respectively. Minor metabolites in these species include tapentadol‐O‐sulfate, and desmethyltapentadol (Howard et al. 2018; Ortho‐McNeil‐Janssen Pharmaceuticals Inc., n.d.). Although notably, tapentadol‐glucuronide was the only metabolite measured in the current study, it appears that this is the major metabolite in horses as well. As discussed above, the metabolic ratio (AUCtapentadol glucuronide:AUCtapentadol) varied widely between horses when administered the same dose. One horse had a markedly lower metabolic ratio compared to the other horses when administered the same dose. This finding was consistent for that horse at all doses. While the specific metabolic enzyme responsible for glucuronidation of tapentadol in horses has not been elucidated, in humans, this metabolic reaction is attributable to UGT1A9 and UGT2B7 (Kneip et al. 2008; Terlinden et al. 2007). Genetic polymorphisms in genes encoding UGT enzymes, leading to alterations in the metabolism of substrates for these enzymes have been identified in humans (Miners et al. 2002). Although much work remains to be done, if these polymorphisms exist in horses, this may provide an explanation for differences in metabolism and hence the metabolic ratio in horses. In a previous pharmacokinetic study in humans, factors (covariates) such as sex, age, body fat, or hepatic function have been noted to influence the pharmacokinetics of tapentadol (Xu et al. 2010). While the small sample size in the current study precluded population pharmacokinetic modeling and assessment of the effects of covariates on the pharmacokinetics of tapentadol in horses, physiological variation may explain some of the variance in pharmacokinetic parameters such as Cmax, AUC, and clearance in equines. Based on the variability in pharmacokinetic parameters and subjective observations of differences in body composition, as well as age differences, additional studies with more horses, which would allow for population pharmacokinetic modeling and subsequently the assessment of covariates, are warranted. Previous pharmacokinetic studies in pediatric (12 to < 18 years) and adult human patients determined that a 1 mg/kg dose of tapentadol was efficacious for the treatment of moderate pain, with efficacy at concentrations 67.0 ± 26.3 ng/mL and 72.1 ± 29.0 ng/mL respectively (Muse et al. 2019). The concentration data generated in the current study indicates dosing between 3 mg/kg (Cmax = 39.8 ± 53.8) and 5 mg/kg (Cmax = 210.6 ± 234.4) achieved drug levels comparable to those deemed efficacious for the treatment of pain in humans. Similar to a previous report of tapentadol administration in horses, whereby a dose of 0.5 mg/kg was administered orally for 4 weeks (Costa et al. 2024), in the current study, tapentadol was well tolerated at all doses studied. Subjectively, some horses in the 3 mg/kg (2 horses) and 5 mg/kg (1 horse) dose groups did appear slightly sedate (lowered head, drooping lip); however, activity, as measured by the number of steps and heart rate, was not significantly decreased from baseline at these points. Opioid administration is associated with dose dependent hyperlocomotion in horses. While significant changes in locomotion were noted across all administered doses of tapentadol, significant increases or decreases do not appear to correlate with plasma‐drug concentrations, and significant differences in step count were not observed when plasma‐drug concentrations peaked during the 5 mg/kg oral and 0.32 mg/kg IV doses (the doses at which plasma‐drug concentration reached the highest concentrations). Therefore, changes in step count observed in the current study are most likely not attributable to drug administration but more likely due to external stimuli. Similarly, minimal changes were noted in heart rate (Figure 3). An increased heart rate in a single individual resulted in large standard deviations at some timepoints, which may have skewed the data. The individual was under observation at these timepoints and was calm without additional abnormal behaviors. The absence of drug‐related physiological changes would be consistent with previous pharmacodynamic studies in dogs (Howard et al. 2018). Gastrointestinal borborygmi was only minimally affected by tapentadol administration at the doses studied here, with significant changes noted at only a couple of time points postadministration at each dose. When interpreting these findings, it is important to note that while auscultation of gastrointestinal borborygmi is a commonly used practice in a clinical setting, it is a subjective measure of gastric motility and may be subject to variation dependent on observer. Overall, the physiological data reported here suggest that tapentadol, at the doses studied, has a favorable safety profile in horses. When reviewing this data, it is important to note a few limitations. One limitation is the small sample size. Additional horses would increase the statistical power with respect to both pharmacokinetic and pharmacodynamic assessments. Additionally, it is important to note that the observers were not blinded to the treatment. The sequential escalating study design precluded blinding, but it is important to recognize the potential bias this may introduce. Another notable limitation was technical issues encountered with some of the step counters and Holter monitors, resulting in missing data for some horses at some doses and at certain time points. This could affect the statistical analysis. This study provides the first comprehensive characterization of tapentadol's pharmacokinetics in horses. Importantly, tapentadol was generally well tolerated at the doses studied. Additionally, while studies to determine the effective concentration in horses are needed, plasma concentrations following oral administration of 3 and 5 mg/kg tapentadol resulted in concentrations associated with analgesic efficacy in humans. The observed interindividual variability in pharmacokinetic parameters may be a result of physiological or metabolic differences and underscores the need for study of additional horses. Author Contributions H.K.K. and K.R.M. conceived the work. H.K.K. and K.R.M. designed the study. A.D.L., K.R.M., H.K.K., D.S.M., and P.H.K. conducted the study and participated in data analysis. All authors contributed to manuscript preparation and reviewed and approved the final manuscript. Funding This work was supported by Center for Equine Health, School of Veterinary Medicine, University of California, Davis, Kenneth L Maddy Equine Analytial Chemistry Laboratory Program, NIH Pharmacology Training Grant (T32GM144303). Ethics Statement The authors confirm that the ethical policies of the journal, as noted on the journal's author guidelines page, have been adhered to and the appropriate ethical review committee approval has been received. The authors confirm that they have adhered to US standards for the protection of animals used for scientific purposes. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgements Financial support for this study was provided by the Center for Equine Health, School of Veterinary Medicine, University of California, Davis, and the Kenneth L. Maddy Equine Analytical Chemistry Laboratory program funds. Thank you to Dr. Camilo J. Morales, Sandy Yim, Stacy Steinmetz, and Meagan Traynham for technical assistance. Annabella Lynch is a recipient of a NIH funded Pharmacology training grant: T32GM144303. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.